Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and Cara Therapeutics (CARA – Research Report) with bullish sentiments.
Celcuity (CELC)
In a report released today, Gil Blum from Needham maintained a Buy rating on Celcuity, with a price target of $24.00. The company’s shares closed last Wednesday at $18.16, close to its 52-week high of $18.95.
According to TipRanks.com, Blum is a 4-star analyst with an average return of 7.9% and a 46.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Recursion Pharmaceuticals, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Celcuity is a Strong Buy with an average price target of $32.00.
See the top stocks recommended by analysts >>
Cara Therapeutics (CARA)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Cara Therapeutics, with a price target of $5.00. The company’s shares closed last Wednesday at $0.87, close to its 52-week low of $0.50.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of 3.5% and a 42.3% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cara Therapeutics with a $7.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CELC: